FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205306698> ?p ?o ?g. }

• W4205306698 endingPage "306" @default.
• W4205306698 startingPage "306" @default.
• W4205306698 abstract "306 Background: The combination of paclitaxel (PTX) plus ramucirumab (RAM) has been the standard regimen for advanced gastric cancer (GC) or gastro-esophageal junction cancer (GJC) patients (pts) who were treated with fluoropyrimidine-containing regimen. In a phase 2 trial, it was showen that nab-PTX plus RAM has promising activity (objective response rate [ORR], 55 %; median progression free survival [PFS], 7.6 months) [Bando H, et al. Eur J Cancer 2018] and is, therefore, a treatment option. However, high incidence of myelosuppression led to discontinuation of the nab-PTX. Therefore, we conducted this study to investigate whether schedule modification to biweekly nab-PTX plus RAM therapy is safe and effective. Methods: Pts with GC or GJC treated with fluoropyrimidine-containing regimen were enrolled and received nab-PTX (100 mg/m 2 ) on days 1, 8, and 15 and RAM (8 mg/kg) on days 1 and 15 of a 28-day cycle. The treatment schedule of pts with severe myelosuppression during the first cycle was modified to biweekly therapy from the second cycle. The primary endpoint was PFS in modified pts. Secondary endpoints included ORR, disease control rate (DCR), overall survival (OS), and safety. The exploratory analysis evaluated PFS and OS in pts who continued standard-schedule therapy. Based on the hypothesis that biweekly nab-PTX plus RAM therapy would improve PFS from 4.5 months to 7.0 months, 40 pts were required for a power of 0.8 with a one-sided α of 0.05. Results: Of the 81 pts who were enrolled, 76 pts received standard nab-PTX plus RAM in the first cycle and 47 pts (58%) were modified to the bi-weekly therapy. Pts characteristics in the modified pts were as follows: median age, 70 years; male, 72%; ECOG PS 0, 81%; and poorly differentiated adenocarcinoma or signet ring cell carcinoma, 45%. The median relative dose intensities of the entire period and after modification were 66% and 60%, respectively. In the modified pts, median PFS was 4.7 months (95% Confidence Interval [CI]: 3.7–5.6), median OS was 13.9 months (95% CI: 9.1–16.9), ORR was 25% (95% CI: 11–39), and DCR was 75% (95% CI: 61–89). Tumor shrinkage was observed in 61% of the pts (n = 36) with measurable lesion. In pts who could continue standard-schedule therapy, median PFS was 2.7 months (95% CI: 1.8–4.0) and median OS was 8.0 months (95% CI: 5.6–14.7). Severe (Grade >3) adverse events after modification were neutropenia (55%), anemia (13%), hypertension (17%), and peripheral sensory neuropathy (13%). Conclusions: Our study could not meet the primary endpoint for PFS. However, PFS in pts with standard-schedule therapy was numerically lower than that in the modified pts. The modification to biweekly schedule might be considered to be a treatment option for GC/GJC pts with severe myelosuppression in second-line nab-PTX plus RAM therapy. Clinical trial information: jRCTs031180061." @default.
• W4205306698 created "2022-01-26" @default.
• W4205306698 creator A5001002762 @default.
• W4205306698 creator A5001214587 @default.
• W4205306698 creator A5008014743 @default.
• W4205306698 creator A5008895945 @default.
• W4205306698 creator A5011441657 @default.
• W4205306698 creator A5011507410 @default.
• W4205306698 creator A5012441434 @default.
• W4205306698 creator A5013994958 @default.
• W4205306698 creator A5022410093 @default.
• W4205306698 creator A5026657616 @default.
• W4205306698 creator A5029308720 @default.
• W4205306698 creator A5034040686 @default.
• W4205306698 creator A5034529454 @default.
• W4205306698 creator A5043000641 @default.
• W4205306698 creator A5051327921 @default.
• W4205306698 creator A5052598485 @default.
• W4205306698 creator A5062565190 @default.
• W4205306698 creator A5062868734 @default.
• W4205306698 creator A5073926001 @default.
• W4205306698 creator A5076417403 @default.
• W4205306698 date "2022-02-01" @default.
• W4205306698 modified "2023-09-26" @default.
• W4205306698 title "A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX trial (JACCRO GC-09)." @default.
• W4205306698 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.306" @default.
• W4205306698 hasPublicationYear "2022" @default.
• W4205306698 type Work @default.
• W4205306698 citedByCount "0" @default.
• W4205306698 crossrefType "journal-article" @default.
• W4205306698 hasAuthorship W4205306698A5001002762 @default.
• W4205306698 hasAuthorship W4205306698A5001214587 @default.
• W4205306698 hasAuthorship W4205306698A5008014743 @default.
• W4205306698 hasAuthorship W4205306698A5008895945 @default.
• W4205306698 hasAuthorship W4205306698A5011441657 @default.
• W4205306698 hasAuthorship W4205306698A5011507410 @default.
• W4205306698 hasAuthorship W4205306698A5012441434 @default.
• W4205306698 hasAuthorship W4205306698A5013994958 @default.
• W4205306698 hasAuthorship W4205306698A5022410093 @default.
• W4205306698 hasAuthorship W4205306698A5026657616 @default.
• W4205306698 hasAuthorship W4205306698A5029308720 @default.
• W4205306698 hasAuthorship W4205306698A5034040686 @default.
• W4205306698 hasAuthorship W4205306698A5034529454 @default.
• W4205306698 hasAuthorship W4205306698A5043000641 @default.
• W4205306698 hasAuthorship W4205306698A5051327921 @default.
• W4205306698 hasAuthorship W4205306698A5052598485 @default.
• W4205306698 hasAuthorship W4205306698A5062565190 @default.
• W4205306698 hasAuthorship W4205306698A5062868734 @default.
• W4205306698 hasAuthorship W4205306698A5073926001 @default.
• W4205306698 hasAuthorship W4205306698A5076417403 @default.
• W4205306698 hasConcept C121608353 @default.
• W4205306698 hasConcept C126322002 @default.
• W4205306698 hasConcept C141071460 @default.
• W4205306698 hasConcept C143998085 @default.
• W4205306698 hasConcept C168563851 @default.
• W4205306698 hasConcept C203092338 @default.
• W4205306698 hasConcept C207103383 @default.
• W4205306698 hasConcept C2776694085 @default.
• W4205306698 hasConcept C2776999253 @default.
• W4205306698 hasConcept C2777292972 @default.
• W4205306698 hasConcept C2778715236 @default.
• W4205306698 hasConcept C2779551604 @default.
• W4205306698 hasConcept C2781413609 @default.
• W4205306698 hasConcept C31760486 @default.
• W4205306698 hasConcept C44249647 @default.
• W4205306698 hasConcept C71924100 @default.
• W4205306698 hasConcept C90924648 @default.
• W4205306698 hasConceptScore W4205306698C121608353 @default.
• W4205306698 hasConceptScore W4205306698C126322002 @default.
• W4205306698 hasConceptScore W4205306698C141071460 @default.
• W4205306698 hasConceptScore W4205306698C143998085 @default.
• W4205306698 hasConceptScore W4205306698C168563851 @default.
• W4205306698 hasConceptScore W4205306698C203092338 @default.
• W4205306698 hasConceptScore W4205306698C207103383 @default.
• W4205306698 hasConceptScore W4205306698C2776694085 @default.
• W4205306698 hasConceptScore W4205306698C2776999253 @default.
• W4205306698 hasConceptScore W4205306698C2777292972 @default.
• W4205306698 hasConceptScore W4205306698C2778715236 @default.
• W4205306698 hasConceptScore W4205306698C2779551604 @default.
• W4205306698 hasConceptScore W4205306698C2781413609 @default.
• W4205306698 hasConceptScore W4205306698C31760486 @default.
• W4205306698 hasConceptScore W4205306698C44249647 @default.
• W4205306698 hasConceptScore W4205306698C71924100 @default.
• W4205306698 hasConceptScore W4205306698C90924648 @default.
• W4205306698 hasFunder F4320311653 @default.
• W4205306698 hasIssue "4_suppl" @default.
• W4205306698 hasLocation W42053066981 @default.
• W4205306698 hasOpenAccess W4205306698 @default.
• W4205306698 hasPrimaryLocation W42053066981 @default.
• W4205306698 hasRelatedWork W1051628 @default.
• W4205306698 hasRelatedWork W19973245 @default.
• W4205306698 hasRelatedWork W2054286 @default.
• W4205306698 hasRelatedWork W2337926 @default.
• W4205306698 hasRelatedWork W3657330 @default.
• W4205306698 hasRelatedWork W370487 @default.
• W4205306698 hasRelatedWork W4112738 @default.
• W4205306698 hasRelatedWork W4429043 @default.
• W4205306698 hasRelatedWork W5038423 @default.

• next